SCHEMBL27226792

SCHEMBL27226792

COC(=O)c1ccc([N+](=O)[O-])c(Nc2ccc(CO)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.45
▸ MAPK1 P28482 3/20 0.45
▸ POLB P06746 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ KMT2A Q03164 5/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ MCL1 Q07820 1/20 0.42
▸ PTK2B Q14289 1/20 0.42
▸ GSK3B P49841 3/20 0.40
▸ AURKA O14965 2/20 0.40
▸ GSK3A P49840 2/20 0.40
▸ LMNA P02545 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30814928 1.00 MAPT (0.45) MAPTMAPK1POLBNPC1NFKB1
SCHEMBL30815681 0.86 MAPT (0.43) MAPTMAPK1POLBNPC1NFKB1
SCHEMBL27227742 0.86 MAPT (0.43) MAPTMAPK1POLBNPC1NFKB1
SCHEMBL30815817 0.86 PTK2 (0.43) MAPTMAPK1NPC1NFKB1RAB9A
SCHEMBL27226659 0.86 PTK2 (0.43) MAPTMAPK1NPC1NFKB1RAB9A
SCHEMBL27227216 0.85 MAPT (0.43) MAPTMAPK1NPC1NFKB1RAB9A
SCHEMBL30815765 0.85 MAPT (0.43) MAPTMAPK1NPC1NFKB1RAB9A
SCHEMBL27227583 0.85 MAPT (0.41) MAPTMAPK1POLBNPC1NFKB1
SCHEMBL27227025 0.83 TXNRD1 (0.46) MAPTMAPK1NPC1NFKB1RAB9A
SCHEMBL27227041 0.79 MAPT (0.42) MAPTMAPK1NPC1NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11999730-B1 AKT1 modulators ALTEROME THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
US-20240174667-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-05-30 — — US disclosed
WO-2024073371-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 MAPT 1885/4885MAPK1 124/4885POLB 2786/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 MAPT 1885/4885MAPK1 124/4885POLB 2786/4885
US-11999730-B1 AKT1 modulators AKT1S1, AKT1, AKT2 MAPT 1885/4885MAPK1 124/4885POLB 2786/4885
US-20240174667-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 MAPT 1885/4885MAPK1 124/4885POLB 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback